Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient

Lung Cancer. 2015 Feb;87(2):204-6. doi: 10.1016/j.lungcan.2014.12.008. Epub 2014 Dec 19.

Abstract

We present a very interesting case of lung adenocarcinoma carrying an uncommon EGFR exon 19 insertion with concomitant PIK3CA mutation showing dramatic and persisting improvement upon erlotinib therapy, after progression during PI3K inhibitor.

Keywords: EGFR; Erlotinib; Gene mutations; NSCLC; PI3K inhibitor; PI3KCA.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / mortality
  • Adenocarcinoma of Lung
  • Adult
  • Antineoplastic Agents / therapeutic use*
  • DNA Mutational Analysis
  • ErbB Receptors / genetics*
  • Female
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / mortality
  • Mutation*
  • Nuclear Proteins / genetics*
  • Protein Kinase Inhibitors / therapeutic use*
  • Tomography, X-Ray Computed
  • Transcription Factors / genetics*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Nuclear Proteins
  • PI3KCA protein, human
  • Protein Kinase Inhibitors
  • Transcription Factors
  • ErbB Receptors